These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 24120672

  • 1. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.
    Vaccine; 2014 May 01; 32(21):2507-17. PubMed ID: 24120672
    [Abstract] [Full Text] [Related]

  • 2. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2013 Dec 05; 31(50):6034-40. PubMed ID: 24055306
    [Abstract] [Full Text] [Related]

  • 4. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY.
    Vaccine; 2012 Oct 05; 30(45):6427-35. PubMed ID: 22910287
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.
    Vaccine; 2011 Aug 05; 29(34):5666-74. PubMed ID: 21699951
    [Abstract] [Full Text] [Related]

  • 6. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.
    N Engl J Med; 2004 Nov 25; 351(22):2295-301. PubMed ID: 15525714
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.
    Hum Vaccin Immunother; 2014 Nov 25; 10(6):1701-10. PubMed ID: 24732325
    [Abstract] [Full Text] [Related]

  • 12. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G.
    Vaccine; 2012 Apr 16; 30(18):2908-13. PubMed ID: 22342501
    [Abstract] [Full Text] [Related]

  • 13. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.
    Vaccine; 2008 Dec 02; 26(51):6614-9. PubMed ID: 18930093
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
    Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ.
    J Infect Dis; 2009 Jul 15; 200(2):172-80. PubMed ID: 19508159
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH, Witham K, Depelsenaire ACI, Veitch M, Wells JW, Wheatley A, Pryor M, Lickliter JD, Francis B, Rockman S, Bodle J, Treasure P, Hickling J, Fernando GJP.
    PLoS Med; 2020 Mar 15; 17(3):e1003024. PubMed ID: 32181756
    [Abstract] [Full Text] [Related]

  • 17. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B, Kositanont U, Rittayamai N, Niyomthong P, Songserm T, Maranetra KN, Rattanasaengloet K, Nana A.
    Hum Vaccin Immunother; 2016 Jul 02; 12(7):1728-37. PubMed ID: 27153158
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.
    Vaccine; 2009 Dec 09; 27(52):7304-12. PubMed ID: 19849996
    [Abstract] [Full Text] [Related]

  • 20. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P.
    Vaccine; 2007 Jan 08; 25(4):659-63. PubMed ID: 17011678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.